Segall Bryant & Hamill LLC Has $4.17 Million Stock Position in Haemonetics Corporation $HAE

Segall Bryant & Hamill LLC boosted its position in shares of Haemonetics Corporation (NYSE:HAE) by 213.8% in the 1st quarter, HoldingsChannel reports. The firm owned 73,992 shares of the medical instruments supplier’s stock after buying an additional 50,412 shares during the period. Segall Bryant & Hamill LLC’s holdings in Haemonetics were worth $4,170,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of HAE. Kemnay Advisory Services Inc. acquired a new position in Haemonetics during the 4th quarter worth $26,000. Leonteq Securities AG bought a new position in shares of Haemonetics in the 4th quarter worth $30,000. EverSource Wealth Advisors LLC grew its stake in shares of Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 396 shares during the period. Kestra Advisory Services LLC bought a new stake in Haemonetics in the fourth quarter valued at about $34,000. Finally, Bayforest Capital Ltd acquired a new position in Haemonetics in the fourth quarter valued at about $40,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on HAE shares. Barrington Research decreased their target price on Haemonetics from $94.00 to $89.00 and set an “outperform” rating for the company in a research report on Tuesday, May 12th. Citigroup reissued a “buy” rating on shares of Haemonetics in a research note on Wednesday, July 29th. Wall Street Zen upgraded shares of Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. Bank of America raised shares of Haemonetics from a “neutral” rating to a “buy” rating and upped their target price for the company from $72.00 to $80.00 in a research note on Friday, May 22nd. Finally, Mizuho increased their target price on shares of Haemonetics from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $78.89.

Haemonetics Trading Up 1.5%

NYSE HAE opened at $86.78 on Tuesday. The firm has a market cap of $3.94 billion, a P/E ratio of 42.96, a P/E/G ratio of 1.73 and a beta of 0.52. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.95 and a quick ratio of 1.87. The stock’s 50-day moving average is $75.53 and its 200-day moving average is $66.14. Haemonetics Corporation has a one year low of $47.31 and a one year high of $88.59.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, topping the consensus estimate of $1.28 by $0.01. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The firm had revenue of $346.35 million for the quarter, compared to the consensus estimate of $336.83 million. During the same period last year, the company posted $1.24 EPS. The business’s quarterly revenue was up 4.8% on a year-over-year basis. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Sell-side analysts anticipate that Haemonetics Corporation will post 5.21 earnings per share for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.